




Republic of the Philippines
Department of Health
OFFICE OF THE SECRETARY

**MEDICINES RECOMMENDED FOR NON-INCLUSION IN THE PHILIPPINE
NATIONAL FORMULARY (PNF)**

As of 23 February 2021, the Health Technology Assessment Council (HTAC) has finished the assessment and deliberation on **pazopanib as second-line treatment for metastatic soft-tissue sarcoma**. The evaluation aims to appraise existing relevant information as well as the report of the Evidence Review Group on clinical efficacy and safety, and economic impact.

The HTAC hereby makes public the **recommendation for disapproval of the inclusion** attached in the Evidence Summary with supporting studies informing their recommendation. All comments, inputs and/or appeals may be submitted until **09 March 2021** for consideration of the HTAC through email at hta@doh.gov.ph.

Should you wish to submit hard copies of your submissions, you may drop them off at the 4th floor, Philippine Blood Disease and Transfusion Center, Lung Center Compound, Quezon Avenue, Quezon Avenue, Quezon City. Appeals shall no longer be entertained after the prescribed deadline.


ANNA MELISSA S. GUERRERO, MD, MPH (HTA)
Head, Health Technology Assessment Unit
Health Regulation Team